Phase 3 N=222 Adjusted Fibrinogen Replacement Strategy
Bleeding Disorder · Hypofibrinogenemia; Acquired
Primary: Intra-operative Blood Loss — 1380.7; 1660.13 mL — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=450 Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD
Post Traumatic Stress Disorder
Primary: Change From Baseline in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Score — -19.19; -13.61 score on a scale — p=0.0007
Phase 3 N=2,285 SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection) · COVID-19
Primary: Percentage of Subjects Hospitalized for Any Cause or Died Due to Any Cause — 7; 2; 0; 0 Participants — p=0.954
Phase 3 N=5 Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer
Metastatic Lung Cancer · Stage IV Lung Cancer
Primary: Number of Participants With Progression-free Survival (PFS) After Completion of First Line Standard of Care Systemic Therapy — 1; 0 Participants
Phase 3 N=61 A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.
Fibrodysplasia Ossificans Progressiva (FOP)
Primary: Number of Participants With All Treatment-emergent Adverse Events (TEAEs), Serious and Non-serious Treatment-emergent Adverse Events and Serious and Non-serious…
Phase 3 N=11,942 A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age
SARS-CoV-2
Primary: Parts 1, 2, and 3: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) — 216; 221; 93; 24 Participants
Phase 3 N=8,061 A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age
SARS-CoV-2 · Influenza
Primary: Geometric Mean (GM) Level of Antibodies for Influenza, as Measured by Hemagglutination Inhibition (HAI) Assay — 120.5; 104.3; 137.7; 97.3 titer
Phase 3 N=984 A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before
Diabetes Mellitus, Type 2
Primary: Change in Glycated Haemoglobin (HbA1c) — -1.55; -1.35 Percentage of HbA1c — p=<0.0001
Phase 3 N=582 A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)
Diabetes Mellitus, Type 1
Primary: Change in Glycosylated Haemoglobin (HbA1c) at Week 26 — -0.47; -0.51 Percentage of HbA1c — p=0.0065
Phase 3 N=243 Safety and Efficacy of Chlorthalidone + Amiloride to Elderly Patients Treatment With Arterial Hypertension
Arterial Hypertension
Primary: Number of Subjects With Serum Potassium Levels Below 4.0 mEq/l at Visit 4 — 18; 19; 25; 51 Participants
Phase 3 N=365 Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose
Dengue Fever
Primary: Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Period Prior to Booster at Visit 1 (Month 0 [Day 1]) — 76.8; 88.6…
Phase 3 N=239 Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI
Corona Virus Infection
Primary: Percentage of Participants With WHO Clinical Progression Scale > 5 at Day 4 -- Severe COVID Population (WHO Clinical Progression Scale =5 at Baseline) — 26; 26…
Phase 3 N=62 Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia (CAH)
Primary: Adult Height Relative to General Population — -0.34; -0.6 Standard Deviation Score (SDS) units
Phase 3 N=354 Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.
Dyslipidemias · High Cholesterol · Hypercholesterolemia
Primary: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] — .25; -36.05 percent change from baseline — p=<.0001
Phase 3 N=178 An Evaluation of the Safety of CSF-1 in Presbyopic Subjects
Presbyopia
Primary: Number of Participants With Treatment Emergent Adverse Events. — 43; 16 Participants